BridgeBio Oncology Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- BridgeBio Oncology Therapeutics Inc.
- Former names
- Helix Acquisition Corp. II
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BBOT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001869105
Board of directors
-
Albert A. Holman III · DirectorSince 2025
- Since 2024
-
Eli M. Wallace · Director · Chief Executive OfficerSince 2025
-
Frank Mccormick · DirectorSince 2025
-
Jake Bauer · DirectorSince 2025
- Since 2024
- Since 2024
-
Michelle Doig · DirectorSince 2025
-
Neil Kumar · DirectorSince 2025
-
Pedro Beltran · Director · President and CEOSince 2026
-
Peter F. Lebowitz · DirectorSince 2026
-
Praveen P. Tipirneni · DirectorSince 2025
-
Raymond J. Kelleher · DirectorSince 2025
Chief executives
Pedro Beltran
· President and CEO
Dates unknown
Bihua Chen
· CEO and Chairperson
Since February 2024
Eli M. Wallace
· Chief Executive Officer
Since August 2025
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
Board connections
7 of this board's directors also sit on 16 other boards.
- via Bihua Chen, John P. Schmid and Mark C. McKenna
- via Bihua Chen and John P. Schmid
- via Frank Mccormick and Neil Kumar
- via John P. Schmid
- via Bihua Chen
- via John P. Schmid
- via Jake Bauer
- via Bihua Chen
- via John P. Schmid
- via Mark C. McKenna
- via Jake Bauer
- via Neil Kumar
- via Mark C. McKenna
- via Mark C. McKenna
- via Praveen P. Tipirneni
- via John P. Schmid
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Cobo Marc Officer (Principal Accounting Officer) | Grant or award | +9,038 | — | — |
| Sep 10, 2026 | Cobo Marc Officer (Principal Accounting Officer) | Shares withheld for tax | −203 | $5.52 | $1,121 |
| Jul 1, 2026 | Pedro Beltran Director, Officer (President and CEO) | Shares withheld for tax | −1,047 | $7.80 | $8,167 |
| Jul 1, 2026 | Yong Ben Officer (Chief Med & Dev Officer) | Shares withheld for tax | −1,047 | $7.80 | $8,167 |
| Jul 1, 2026 | Elmelech Idan Officer (COO & Principal Financial Ofcr) | Shares withheld for tax | −343 | $7.80 | $2,675 |
| Jul 1, 2026 | Cobo Marc Officer (Principal Accounting Officer) | Shares withheld for tax | −125 | $7.80 | $975 |
| Jul 1, 2026 | Bihua Chen Director, 10% owner | Other | −4,528,186 | — | — |
| Jul 1, 2026 | Bihua Chen Director, 10% owner | Other | +2,692,459 | — | — |
| Jul 1, 2026 | Bihua Chen Director, 10% owner | Other | +1,704,862 | — | — |
| Jul 1, 2026 | Bihua Chen Director, 10% owner | Other | +130,865 | — | — |
| Apr 1, 2026 | Yong Ben Officer (Chief Med & Dev Officer) | Shares withheld for tax | −1,047 | $9.03 | $9,454 |
| Apr 1, 2026 | Pedro Beltran Director, Officer (President and CEO) | Shares withheld for tax | −1,047 | $9.03 | $9,454 |
| Apr 1, 2026 | Mehra Uneek Former Officer | Shares withheld for tax | −524 | $9.03 | $4,732 |
| Mar 10, 2026 | Mehra Uneek Officer (Chief Financial Officer) | Grant or award | +23,330 | — | — |
| Mar 10, 2026 | Beltran Pedro Officer (Chief Scientific Officer) | Grant or award | +46,670 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.